Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Piper Sandler Downgrades Immunogen to Neutral, Raises Price Target to $31

Author: Benzinga Newsdesk | December 04, 2023 09:06am
Piper Sandler analyst Joseph Catanzaro downgrades Immunogen (NASDAQ:IMGN) from Overweight to Neutral and raises the price target from $24 to $31.

Posted In: IMGN

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist